Researchers have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia, a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.
Researchers have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia, a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.